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Staphylococcus aureus is a Gram-positive pathogen that can cause various diseases 
including skin and soft tissue infections, pneumonia, endocarditis, and sepsis. 
Moreover, S. aureus is adept at acquiring antibiotic resistance. Methicillin-resistant 
S. aureus (MRSA) is a serious threat in healthcare settings and in the communities. 
Infections by vancomycin-resistant S. aureus and multidrug-resistant S. aureus have 
also been increasing. Therefore, a novel strategy to combat antibiotic-resistant S. 
aureus infections is needed. Short-chain fatty acids (SCFAs) are metabolites 
produced by gut microbiota by fermentation of dietary fibers and non-digestible 
carbohydrates. The major SCFAs in the gut are acetate, butyrate, and propionate. 
Apart from their immunomodulatory roles in the host, SCFAs have been suggested 
to have antimicrobial effects on some pathogenic bacteria such as Helicobacter 
 
pylori and Salmonella enterica. However, the effects of SCFAs on S. aureus have 
not been extensively studied. The aim of this study was to investigate the effects of 
SCFAs, acetate, propionate or butyrate, on S. aureus growth and infection. 
 
Methods 
MRSA USA300 was cultured in the presence or absence of various doses of SCFAs, 
acetate, propionate, or butyrate. Optical density at 600 nm was measured to examine 
bacterial growth. The effects of SCFAs on multidrug-resistant clinical isolates were 
also investigated. The minimum inhibitory concentration/minimum bactericidal 
concentration test was conducted to determine if SCFAs had bacteriostatic or 
bactericidal effects. Bacterial morphology was observed under the scanning electron 
microscope. To determine the effects of SCFAs on MRSA skin infection, mice were 
subcutaneously infected with MRSA, with or without acetate, propionate, or butyrate. 
Three days post-infection, abscess size and weight were measured, and homogenates 
of abscesses were used to measure the bacterial load. The expression of interleukin 
(IL)-1β, a major cytokine in skin infection, and IL-6, a proinflammatory cytokine, in 
homogenates was measured by enzyme-linked immunosorbent assay. Abscesses 
were cryosectioned and subjected to histological analysis by hematoxylin and eosin 
staining and Gram staining. The effect of propionate treated after skin infection was 
initiated was also investigated. To determine the role of cell wall components in the 
growth inhibition, growth studies were conducted with S. aureus deficient of 
lipoteichoic acid (ltaS), wall teichoic acid (tagO), lipoprotein (lgt), or D-
alanylation of teichoic acids (dltA). A D-alanylation inhibitor of teichoic acids, 
amsacrine, was used for MRSA. Amsacrine and propionate were co-treated in vitro 
and in vivo. To study the action mechanism at the molecular level, the Nebraska 
Transposon Mutant Library of MRSA USA300 was used for growth studies. The 





Of the three SCFAs, propionate most potently inhibited the growth of MRSA 
USA300, inhibiting its growth in a dose-dependent manner. Butyrate had some 
inhibitory effects, while acetate had minimal effects. Propionate had a bacteriostatic 
effect, only inhibiting bacterial growth without killing it, and did not cause physical 
damage. Propionate inhibited the growth of multidrug-resistant clinically isolated 
strains. Propionate ameliorated MRSA skin infection, by lowering abscess formation 
and bacterial load, without having toxic effects in mice at the concentration used. 
Excessive cytokine expression, namely IL-1β and IL-6, also decreased. Propionate 
also reduced abscess formation when treated after MRSA infection was initiated. S. 
aureus deficient of lipoteichoic acids or wall teichoic acids was more susceptible to 
propionate than the wild-type. In addition, S. aureus deficient of D-alanine motifs 
common in teichoic acids was more susceptible to propionate. Concordantly, MRSA 
treated with amsacrine, which inhibits D-alanylation of teichoic acids, was more 
susceptible to propionate. Co-treatment of amsacrine and propionate further 
ameliorated MRSA skin infection. Both propionate and amsacrine were not toxic at 
the concentrations used. MRSA deficient of a gluconeogenesis enzyme or 
tricarboxylic acid cycle enzyme was more susceptible to propionate, while MRSA 
deficient of a glycolytic enzyme was not, suggesting that propionate may affect 
bacterial metabolism. The growth of Streptococcus pneumoniae or Enterococcus 
faecium was potently inhibited, while that of Staphylococcus epidermidis or 
Enterococcus faecalis was moderately inhibited by propionate. The growth of 
Streptococcus gordonii or Lactobacillus plantarum was not inhibited by propionate. 
 
Conclusions 
Collectively, propionate inhibited the growth of S. aureus, including clinically 
isolated multidrug-resistant S. aureus, and decreased the pathology of MRSA skin 
infection. Since propionate did not have toxic effects in vivo, and is a metabolite 
present in our body, it is likely to have fewer or no side effects in the host compared 
with other antibiotics. Moreover, as co-treatment of propionate and a D-alanylation 
 
inhibitor, both of which were not toxic in the concentrations used, further reduced 
pathology, a combination therapy may be an alternative strategy to treat multidrug-
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Chapter I. Introduction 
Staphylococcus aureus is a Gram-positive bacterium that frequently colonizes 
humans. It is a major pathogen that causes various diseases including skin and soft 
tissue infections (SSTIs), pneumonia, and endocarditis, and is the most frequent 
bacterium associated with sepsis [1, 2]. SSTIs are the most common forms of S. 
aureus infections and can lead to the spread of S. aureus to other parts of the body, 
often resulting in serious diseases such as bacteremia or pneumonia [3]. Moreover, 
S. aureus is the most common cause of SSTIs among patients in the emergency 
department [4]. In S. aureus infections, neutrophils are first recruited to the site of 
infection, where they produce interleukin (IL)-1β, a cytokine which plays an 
important role in immunity against S. aureus infection, but which can also cause 
immunopathology [5, 6]. In addition, S. aureus is able to evade the host’s immune 
system. It can resist phagocytosis by neutrophils, and resist killing by antimicrobial 
peptides or lysozyme via various mechanisms [7-9]. Furthermore, S. aureus is able 
to resist killing inside neutrophils and survive inside phagosomes [10]. It has been 
suggested that S. aureus can take advantage of these cells by residing in them to 
contribute to infection, and disseminate to other parts of the body such as the bone 
or heart [11]. 
 
Since there is no vaccine yet available to prevent S. aureus infections, treatment of 
S. aureus infections mostly relies on antibiotics [12]. However, S. aureus is adept at 
acquiring antibiotic resistance. Methicillin-resistant S. aureus (MRSA) is a serious 
threat in not only healthcare settings but also in the communities, which is predicted 
to kill approximately 19,000 patients per year in the US alone, which is similar to 
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the number of deaths by AIDS, tuberculosis, and hepatitis combined [13, 14]. The 
worldwide prevalence of MRSA is increasing, and interestingly, South Korea has a 
particularly high MRSA prevalence, with 73% of clinical isolates being methicillin-
resistant [15, 16]. SSTIs represent approximately 90% of total infections caused by 
community-acquired MRSA [3]. However, resistance against topical antimicrobials, 
such as fusidic acid, bacitracin, neomycin, or mupirocin, used against S. aureus skin 
infections, has emerged [17-19]. Moreover, infections by vancomycin-resistant S. 
aureus and multidrug-resistant S. aureus have been increasing [20, 21]. In addition, 
emerging resistance to newer classes of antibiotics such as linezolid, and side effects 
of antibiotics are emphasizing the limited treatment options [22-24]. Therefore, a 
novel strategy to combat antibiotic-resistant S. aureus infections is needed. Recently, 
combination therapy and the concept of synthetic lethality have been gaining 
attention as strategies to overcome antibiotic-resistant S. aureus infections [25, 26]. 
Combination therapy has been thought to be more effective and less prone to 
resistance, and has been employed for MRSA infections [27]. 
 
Short-chain fatty acids (SCFAs) are metabolites produced by gut microbiota when 
dietary fibers and non-digestible carbohydrates are fermented in the colon [28]. The 
major SCFAs in humans, acetate, propionate, and butyrate, represent more than 95% 
of total SCFAs, and are produced in a molar ratio of approximately 60:20:20 [29]. 
The concentration of SCFAs is in the range of 70 mM to 140 mM where they are the 
most abundant [30]. SCFAs are produced by many different commensal bacteria via 
diverse pathways. The Bacteroidetes phylum mainly produces acetate and 
propionate, whereas the Firmicutes phylum mainly produces butyrate [31]. SCFAs 
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drain via the portal vein and reach the periphery, including the lung, liver, or bone 
marrow to exert beneficial metabolic effects [30, 32]. In addition, SCFAs are 
produced by commensals in other sites such as the skin as well [33]. SCFAs have 
various roles in the host, often simply acting as energy sources for colonocytes, and 
leading to enhanced mucus and antimicrobial peptides production [34]. Moreover, 
SCFAs regulate the immune system to maintain host immune homeostasis primarily 
in the gut, by inducing regulatory T cell development and helping maintain the 
immune tone [32, 35]. SCFAs can also induce effector T cells, such as Th17 cells, to 
promote immunity [36]. SCFAs and a high fiber diet, which results in an increased 
production of SCFAs, have been considered possible therapeutic modifications for 
inflammatory bowel disease, type 1 diabetes, allergy, and other inflammatory 
conditions [37-39]. 
 
Apart from their immunomodulatory roles in the host, SCFAs have antimicrobial 
effects on some pathogenic bacteria. The degree of toxicity mediated by SCFAs 
varies among different bacterial species. For example, butyrate inhibits the growth 
of Helicobacter pylori by exhibiting destructive effects on its cell envelope [40], and 
regulates the virulence of Salmonella enterica serovars Typhimurium and Enteritidis 
(S. Typhimurium and S. Enteritidis) [41]. Acetic acid inhibits the growth of 
Escherichia coli by interfering with methionine biosynthesis [42]. Propionate 
suppresses S. Typhimurium invasion and also inhibits its growth [43, 44]. 
Furthermore, it has been suggested that the fermentation products of 
Propionibacterium acnes, which contain various metabolites and proteins including 
propionic acid and butyric acid, inhibit S. aureus colonization [45]. Moreover, 
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propionic acid has been suggested to inhibit S. aureus growth by reducing bacterial 
intracellular pH [46]. However, although propionic acid can change the pH of the 
extracellular medium, the effects of the three SCFAs, acetate, propionate, or butyrate, 
which do not affect pH, have not been studied. In this study, the effects of SCFAs, 
which are biocompatible, on S. aureus in vitro and in vivo were studied, and an 
alternative combination treatment strategy to control antibiotic-resistant S. aureus 
infections was investigated. 
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Chapter II. Materials and Methods 
2.1. Reagents and chemicals 
SCFAs, sodium acetate, sodium propionate, and sodium butyrate, were purchased 
from Sigma-Aldrich Inc. (St. Louis, MO, USA). SCFAs were dissolved in 
endotoxin-free distilled water (Dai Han Pharm Co. Ltd., Seoul, Korea), and filtered 
with a syringe filter (0.2 μm) purchased from Corning (Corning, NY, USA) prior to 
use. Luria Bertani (LB) broth was purchased from LPS solution (Daejeon, Korea). 
Trypticase soy broth (TSB), brain heart infusion (BHI), Todd-Hewitt (TH), yeast 
extract, and Bacto agar were purchased from BD Biosciences (Franklin Lakes, NJ, 
USA). Lactobacilli deMan, Rogosa, and Sharpe (MRS) broth was purchased from 
Neogen (Langing, MI, USA). 2,2,2-Tribromoethanol and 2-methyl-2-butanol were 
purchased from Sigma-Aldrich Inc. Amsacrine (AMSA) was purchased from Abcam 
(Cambridge, UK). Hematoxylin and eosin were purchased from Sigma-Aldrich Inc. 
and BBC Biochemical (Mount Vernon, WA, USA), respectively. Crystal violet and 
safranin were purchased from Sigma-Aldrich Inc. Iodide solution was purchased 
from Samchun Chemicals (Seoul, Korea). 
 
2.2. Bacterial strains and culture conditions 
S. aureus strains used in this study are listed in Table 1. MRSA USA300 wild-type 
(WT) and mutants were provided by the Network on Antimicrobial Resistance in S. 
aureus (NARSA) for distribution by BEI Resources, NIAID, NIH: Nebraska 
Transposon Mutant Library Screening Array (NR-48501). Clinically-isolated S. 
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aureus and Staphylococcus epidermidis were obtained from the National Culture 
Collection for Pathogens (Osong, Korea). Strains and isolation sites in parentheses 
are as follows: MRSA NCCP 11485 (urine), 11486 (urine), 14565 (blood), 14566 
(abscess), 14567 (abscess), 14568 (catheter tip), 14569 (abscess), 14748 (nose), 
14750 (blood), 14751 (ear), 14769 (transtracheal aspirates), and vancomycin 
intermediate-resistant S. aureus (VISA) NCCP 13846 (pus), 13853 (pus), and 13863 
(pus), and S. epidermidis NCCP 14768 (blood). These strains were cultured in TSB 
at 37C with shaking. WT S. aureus RN4220 [47] and its lipoteichoic acid (LTA)-
deficient (ltaS) [48], wall teichoic acid (WTA)-deficient (tagO) [49], lipoprotein 
(LPP)-deficient (lgt) [50] mutants, and their complement strains of each 
(ltaS/pM101-ltaS [48], tagO/pStagO [51], lgt/pSlgt [50], and dltA/p0793 [49]) 
were kindly provided by Prof. Bok-Luel Lee (Pusan University, Busan, Korea). WT, 
lgt, lgt/pSlgt, dltA, and dltA/p0793 S. aureus were cultured in LB broth at 37C 
with shaking [49, 50]. ltaS, ltaS/pM101-ltaS, tagO, and tagO/pStagO S. 
aureus were cultured in LB broth at 30C with shaking as previously described [48, 
49]. Enterococcus faecalis ATCC 29212 was obtained from the American Type 
Culture Collection (ATCC, Manassas, VA, USA). Enterococcus faecium KACC 
11954 was obtained from Korean Agricultural Culture Collection (Wanju, Korea). 
Enterococci were cultured in BHI broth with shaking at 37C. Streptococcus 
gordonii CHI, which was kindly provided by Dr. Paul M. Sullam (University of 
California at San Francisco, CA, USA), was cultured in TH broth supplemented with 
0.5% yeast extract (THY) at 37C. Lactobacillus plantarum KCTC 10887BP was 
obtained from Korean Collection for Type Cultures (Jeongeup, Korea), and was 
cultured in MRS broth at 37C. 
7 
Table 1. S. aureus strains used in this study 
 
  
   
Strain Characteristics Source or reference 




RN4220 WT Lab strain [47] 
RN4220 ΔltaS Loss of LTA [48] 
RN4220 ΔtagO Loss of WTA [49] 
RN4220 Δlgt Loss of lipoprotein lipid modification [50] 
RN4220 ΔdltA Loss of D-ala modification in LTA and WTA [49] 
RN4220 ΔltaS/pM101-ltaS ΔltaS strain containing a plasmid harboring the ltaS gene [48] 
RN4220 ΔtagO/pStagO ΔtagO strain containing pStagO plamid [51] 
RN4220 Δlgt/pSlgt Δlgt strain containing a plasmid harboring the lgt gene [50] 
RN4220 ΔdltA/p0793 ΔdltA strain containing plasmid harboring intact dltABCD [49] 
NCCP 11485 
Urine; resistance to methicillin, oxacillin, penicillin, erythromycin, 
cefazolin, amoxicillin/clavulanic acid, gentamicin, tetracycline, 
mupirocin 
National Culture Collection 
for Pathogens 
NCCP 11486 
Urine; resistance to methicillin, oxacillin, penicillin, erythromycin, 
clindamycin, cefazolin, amoxicillin/clavulanic acid, ofloxacin, 
tetracycline, rifampin 
National Culture Collection 
for Pathogens 
NCCP 14565 
Blood; resistance to methicillin, penicillin, tetracycline, linezolid, 
quinupristin/dalfopristin 
National Culture Collection 
for Pathogens 
NCCP 14566 Abscess; resistance to methicillin, penicillin, cefoxitin 
National Culture Collection 
for Pathogens 
NCCP 14567 
Abscess, resistance to methicillin, penicillin, cefoxitin, 
erythromycin, clindamycin, tetracycline 
National Culture Collection 
for Pathogens 
NCCP 14568 
Catheter tip; resistance to methicillin, penicillin, cefoxitin, 
ofloxacin, erythromycin, clindamycin, tetracycline 
National Culture Collection 
for Pathogens 
NCCP 14569 
Abscess; resistance to methicillin, penicillin, cefoxitin, 
erythromycin 
National Culture Collection 
for Pathogens 
NCCP 14748 Nose; resistance to methicillin, penicillin, cefoxitin, erythromycin 
National Culture Collection 
for Pathogens 
NCCP 14750 Blood; resistance to methicillin, penicillin, cefoxitin, erythromycin 
National Culture Collection 
for Pathogens 
NCCP 14751 
Ear; resistance to methicillin, penicillin, cefoxitin, ofloxacin, 
erythromycin, clindamycin, tetracycline 
National Culture Collection 
for Pathogens 
NCCP 14769 Transtracheal aspirates; resistance to methicillin 
National Culture Collection 
for Pathogens 
NCCP 13846 
Pus; intermediate resistance to vancomycin, resistance to 
methicillin, oxacillin, penicillin, erythromycin 
National Culture Collection 
for Pathogens 
NCCP 13853 
Pus; intermediate resistance to vancomycin, resistance to 
methicillin, oxacillin, penicillin, erythromycin, clindamycin, 
amoxicillin/clavulanic acid, ofloxacin, gentamicin, tetracycline 
National Culture Collection 
for Pathogens 
NCCP 13863 
Pus; intermediate resistance to vancomycin, resistance to 
methicillin, oxacillin, penicillin, erythromycin, 
amoxicillin/clavulanic acid, gentamicin, tetracycline 
National Culture Collection 
for Pathogens 
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2.3. Effects of SCFAs or AMSA on bacterial growth in vitro 
The general experimental scheme is illustrated in Fig. 1. A single colony of bacteria 
was inoculated and cultured overnight. One percent of an overnight culture was 
inoculated to fresh medium, in the presence or absence of various doses of SCFAs 
(1.56, 3.13, 6.25, 12.5, 25, 50, or 100 mM) and/or AMSA (1.56, 3.13, 6.25, 10, 12.5, 
20, or 25 μg/ml) in flat bottom, non-coated polystyrene 96-well plates (Thermo 
Scientific, Waltham, MA, USA). Bacteria were cultured at 30 or 37C accordingly 
with or without shaking and optical density at 600 nm was measured using a 
spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). To confirm that 
propionate does not affect the pH, the pH of the extracellular medium was measured 
throughout the growth experiments using pH indicator strips (Whatman pH 
indicators, GE Healthcare, Chicago, IL, USA). To determine synergy, the fractional 
inhibitory concentration index (FICI) was calculated using the checkerboard assay 
as previously described [52, 53] with propionate and AMSA. The FICI was 
interpreted as FICI ≤ 0.5 synergy, 0.5 < FICI ≤ 1 partial synergy, 1 < FICI ≤ 4 additive 





Figure 1. Experimental scheme of in vitro bacterial growth experiments. A single 
colony of bacteria was cultured overnight in media. Then, bacteria were cultured in 
various doses of SCFAs and/or AMSA. Growth was measured by reading optical 
density values at 600 nm. 
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2.4. Minimum inhibitory concentration/minimum bactericidal concentration 
(MIC/MBC) test 
The MIC/MBC test was conducted using the microdilution method adopted from the 
Clinical and Laboratory Standards Institute (CLSI) guidelines [54] with minor 
modifications to determine if the agents used are bacteriostatic or bactericidal. 
Bacteria at 5 × 105 CFU/ml were inoculated in media containing serially diluted 
antimicrobial substances (0, 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250, 500, 1000, 2000, or 
3000 mM SCFAs, with 10 μg/ml AMSA where indicated, or 1.56, 3.13, 6.25, 12.5, 
25, 50, 100, or 200 μg/ml AMSA), and cultured for 24 h. The MIC was defined as 
the minimum concentration that resulted in no visible growth after 24 h. Optical 
density at 600 nm was measured to confirm. To determine the MBC, wells that did 
not result in bacterial growth were inoculated in fresh media, free of antimicrobial 
substances. Optical density at 600 nm was measured after an additional 24 h. The 
MBC was defined as the minimum concentration that resulted in no growth even 
after inoculation in fresh media. 
 
2.5. Scanning electron microscopy 
S. aureus was cultured to mid-log phase, then the optical density at 600 nm was set 
to 0.5. S. aureus was cultured in the presence or absence of 50 mM propionate 
overnight in round-bottom 24-well plates (Thermo Scientific, Waltham., MA, USA) 
at 37C without shaking. The supernatants were removed, and the cells were washed 
with phosphate-buffered saline (PBS). Bacteria were fixed with PBS containing 2% 
paraformaldehyde and 2.5% glutaraldehyde after they were first rinsed with the 
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solution. The samples were washed with PBS, then fixed with 1% osmium tetroxide 
for 1.5 h. Samples were washed with distilled water, and dehydrated through an 
ethanol series: 70, 80, 90, and 95% for 15 min each, then 100% for 15 min three 
times. Then, samples were dried using a critical point dryer (HCP-2, Hitachi, Tokyo, 
Japan), and sputter-coated with platinum using an ion sputter (Quorum Q150T S, 
Quorum Technologies Ltd., East Grinstead, UK). Samples were observed using a 
scanning electron microscope (S-4700, Hitachi, Tokyo, Japan) at 15 kV. 
 
2.6. MRSA skin infection 
All animal experiments were conducted under the approval of Institutional Animal 
Care and Use Committee of Seoul National University (SNU-170518-5 and SNU-
181002-2). Eight- to ten-week-old female C57BL/6 mice were purchased from 
Orient Bio (Seongnam, Korea). Animals were housed in specific pathogen-free 
conditions under a 12 h light-dark cycle. A S. aureus skin infection model was used 
as previously described [55], with slight modifications. The experimental scheme is 
shown in Fig. 2. MRSA was cultured to mid-log phase, washed, and resuspended in 
endotoxin-free distilled water alone, or in endotoxin-free distilled water containing 
50 mM SCFA and/or 10 μg/ml AMSA, to a final concentration of 3 × 107 CFU/ml. 
Control samples containing SCFA and/or AMSA alone were also prepared. Mice 
were anesthetized with a mixture of 2,2,2-tribromoethanol and 2-methyl-2-butanol. 
The flank area of mice was shaved with an electric hair clipper and depilatory cream. 
After disinfecting the injection sites with ethanol, mice were challenged 
subcutaneously with 3 × 106 CFU MRSA in a volume of 100 μl alone, or with SCFA 
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and/or AMSA. Animals were monitored daily for three days. For treatment 
experiments, mice were subcutaneously infected with 3 × 106 CFU MRSA in a 
volume of 100 μl. Propionate was injected 1, 24, and 48 h post-infection (h.p.i.) via 
intra-abscess injection [56]. On day 3, after euthanasia, abscess length and width 
were measured with a digital caliper (Mitutoyo Corporation, Kawasaki, Japan). 
Abscesses were aseptically excised, weighed, and homogenized. Homogenates were 
serially diluted and plated on TSB agar plates to measure bacterial load. To confirm 
that the effect of propionate on host cells is minimal, mice were subcutaneously 
injected with 1 × 108 or 1 × 109 CFU of heat-killed MRSA alone or with 50 mM 






Figure 2. General experimental scheme of in vivo skin infection experiments. 
C57BL/6 mice were anesthetized and shaved in the flank area. Mice were 
subcutaneously infected (A) with 3 × 106 CFU MRSA alone, or with acetate, 
propionate, or butyrate, (B) with endotoxin-free water (vehicle control) or with 
propionate only, (C) with AMSA or AMSA and propionate, (D) with 3 × 106 CFU 
MRSA with or without AMSA alone, (E) with 3 × 106 CFU MRSA with propionate 
or with propionate and AMSA in a volume of 100 μl. Animals were monitored daily 
for three days. On day 3, after euthanasia, abscess length and width were measured. 
Abscesses were aseptically excised and weighed. Abscesses were homogenized, 
serially diluted, and plated on TSB agar plates to measure bacterial load. 
Homogenates of abscesses were centrifuged twice and the supernatants were used to 
measure IL-1β and IL-6 by ELISA. For histological analysis, skin abscesses were 
excised and cryosectioned longitudinally onto slide glasses. The sections were 




2.7. Enzyme-linked immunosorbent assay (ELISA) 
Three days after mouse skin infection, abscesses were homogenized. The 
homogenates were centrifuged twice and the supernatants were stored at -80C until 
use. IL-1β and IL-6 in the supernatants were measured using commercial ELISA kits 
(Biolegend, San Diego, CA, USA). 
 
2.8. Histological analysis 
Three days after mouse skin infection, abscesses were excised and cryosectioned 
longitudinally onto slide glasses at 10 μm using a cryocut microtome 1860 (Leica, 
Wetzlar, Germany). The sections were analyzed by H&E staining or Gram staining. 
 
2.9. Statistical analysis 
All in vitro experiments were conducted at least three times. For each experiment, 
the mean value  standard deviation (SD) were obtained from triplicate samples. For 
in vivo studies, data are represented as mean values  standard error of mean (SEM). 
In vivo data were analyzed with GraphPad Prism software. Statistical significance 
was measured using the paired student’s t-test to compare between the groups. 
Asterisks indicate statistically significant differences; *P < 0.05, **P < 0.01, ***P 
< 0.001, ****P < 0.0001. 
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Chapter III. Results 
3.1. SCFAs inhibit the growth of MRSA 
To determine if SCFAs have effects on the growth of S. aureus, MRSA was cultured 
in the presence of different doses of acetate, propionate, or butyrate, and the growth 
was examined. Acetate had a minimal impact on the growth of MRSA, while 
propionate and butyrate inhibited its growth in a dose-dependent manner (Fig. 3A-
C). Interestingly, the inhibitory property of propionate was maintained until 12 h 
after treatment, whereas the inhibitory effect of butyrate was not (Fig. 3B, C). 
Butyrate only prolonged the lag phase. Next, to investigate if the effects of SCFAs 
are bacteriostatic or bactericidal, the MIC/MBC test was conducted with the 
microdilution method. The effect of acetate was minimal and there was no MIC in 
the concentration range tested (Fig. 3D). The MICs of propionate and butyrate were 
250 and 500 mM, respectively (Fig. 3E, F). There was no MBC for all three SCFAs, 
indicating that SCFAs do not kill MRSA. To confirm that propionate, which was the 
most potent, also had a bacteriostatic effect, the MIC/MBC test was conducted with 
higher concentrations of propionate. There was no MBC even at 3 M propionate (Fig. 
4A). Since agents are considered bacteriostatic when the MBC is greater than four 
times the MIC [57], propionate had a bacteriostatic effect. Moreover, when the 
morphology of S. aureus in the presence or absence of propionate was analyzed with 
scanning electron microscopy, S. aureus treated with propionate did not have 
morphological differences compared to non-treated (NT) S. aureus (Fig. 4B). In 
addition, propionate did not affect the pH of the extracellular medium, and the pH 
was stably maintained above 6 throughout the experiment (Fig. 5). To extend our 
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observations, different strains of clinically isolated antibiotic-resistant S. aureus 
strains were cultured in the presence or absence of propionate or butyrate. Propionate 
and butyrate inhibited the growth of S. aureus, including MRSA and VISA isolated 
from various sites (Table 2). Similar to the results of Fig. 3, butyrate prolonged the 
lag phase of MRSA. The inhibitory effect of propionate was maintained until 
stationary phase for most strains, while that of butyrate was not. These results 




Figure 3. SCFAs dose-dependently attenuate the growth of MRSA. MRSA was 
cultured in the presence or absence of different doses of (A) acetate, (B) propionate, 
or (C) butyrate. Optical density at 600 nm was measured. (D-E) The MIC/MBC test 
was conducted using the microdilution method with (D) acetate, (E) propionate, or 
(F) butyrate. The MIC, the concentration of propionate or butyrate which completely 
inhibited growth, is indicated with an arrow. Data shown are the mean values ± SD 
of triplicate samples and are representative of at least three similar independent 
experiments. NaA, acetate; NaP, propionate; NaB, butyrate. 
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Figure 4. Propionate has a bacteriostatic effect, and does not affect bacterial 
morphology. (A) The MIC/MBC test was conducted with the microdilution method 
with 1, 2, and 3 M propionate. Optical density at 600 nm was measured after 24 h 
(left). Wells that did not show growth were inoculated in propionate-free media, and 
optical density was measured after an additional 24 h (right). The MBC was defined 
as the lowest concentration of propionate that resulted in no growth after inoculation 
in propionate-free media. Data shown are the mean values ± SD of triplicate samples 
and are representative of at least three similar independent experiments. (B) An 
overnight culture of S. aureus RN4220 was cultured until mid-log phase. The 
bacterial optical density was set to 0.5. Then, S. aureus was grown overnight in the 
absence (left panels) or presence (right panels) of 50 mM propionate. The samples 
were fixed, dehydrated, sputter coated with platinum and then observed with the 
scanning electron microscope at 10,000× (upper panels) and 30,000× (lower panels) 
magnification. Scale bars indicate 5 μm and 1 μm for upper and lower panels, 
respectively. NaP, propionate. 
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Figure 5. The pH of the extracellular medium is not greatly affected by 
propionate. The pH of the extracellular medium was measured (A) when MRSA 
USA300 was cultured in the presence of absence of 50 mM propionate or (B) when 
S. aureus RN4220 was cultured in the presence or absence of 12.5 mM propionate, 
with pH indicator strips throughout the experiment. (C) The reference pH strips 
indicating pH 6-8. NaP, propionate. 
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Table 2. The effects of propionate and butyrate on the growth of clinically 
isolated, antibiotic-resistant S. aureus 
 
aOD600 of the same culture; bnot significant compared to NT (P > 0.05) 
†multidrug resistant 




Mid-log phasea  Stationary phasea 
NT 50 mM NaP 50 mM NaB  NT 50 mM NaP 50 mM NaB 
 
Methicillin-resistant S. aureus (MRSA) 
11485† 0.456 0.222 0.105  1.010 0.700 0.427 
11486† 0.462 0.221 0.164  0.950 1.001b 1.022b 
14565† 0.844 0.423 0.265  1.061 0.822 1.027b 
14566† 0.755 0.379 0.184  0.930 0.805 0.867 
14567† 0.444 0.192 0.111  0.860 0.485 0.693 
14568† 0.438 0.220 0.180  0.892 0.947b 0.920b 
14569† 0.763 0.477 0.269  0.966 0.937b 1.044b 
14748† 0.594 0.283 0.351  1.037 0.610 1.017b 
14750† 0.805 0.428 0.275  0.995 0.900 1.026b 
14751† 0.447 0.245 0.194  0.901 0.874 0.896b 
14769 0.489 0.290 0.199  0.898 0.887b 0.904b 
 
Vancomycin intermediate-resistant S. aureus (VISA) 
13846† 0.498 0.247 0.108  1.010 0.727 0.556 
13853† 0.684 0.375 0.645b  0.999 0.848 1.047b 




3.2. Propionate alleviates the pathology of MRSA in skin infection 
As SSTIs represent approximately 90% of MRSA infections [3], the effects of 
SCFAs on MRSA infection in vivo were investigated by using a mouse skin infection 
model. Mice were subcutaneously infected with MRSA with or without acetate, 
propionate, or butyrate. Abscesses formed by day 3 post-infection (Fig. 6A). The 
abscess size and weight were significantly reduced when propionate was injected 
together with S. aureus, while acetate or butyrate did not affect abscesses under the 
same conditions (Fig. 6B, C). When the abscesses were excised, homogenized, 
serially diluted, and plated on TSB agar plates to measure bacterial load, propionate, 
but not acetate or butyrate, significantly lowered the bacterial load in the abscesses 
(Fig. 6D). Moreover, IL-1β, a signature cytokine of S. aureus abscess formation [5], 
and IL-6, a proinflammatory cytokine, were lower in abscesses co-injected with 
propionate than in NT abscesses (Fig. 6E, F). Interestingly, butyrate did not affect 
abscess size, bacterial load, or cytokine expression (Fig. 6A-F), although it had some 
inhibitory effects in vitro. Histological analysis of abscesses demonstrated high 
immune cell infiltration, and bacterial clusters, both indicated with an arrow, in mice 
infected with MRSA (Fig. 6G, left). In propionate-treated mice, there was less cell 
infiltration and a lower number of bacterial clusters (Fig. 6G, right). SCFAs was not 
toxic at the concentrations used, and did not result in pathology (Fig. 7A-D). 
Propionate did not induce cytokine expression in mice (Fig. 7E, F). In addition, 
propionate did not change the size and weight of abscesses formed by injection of 
heat-killed MRSA at two different doses (Fig. 8A-F). To extend our results to more 
reflect actual infection conditions, the effects of propionate when treated after MRSA 
infection was initiated were investigated. When propionate was administered at 1, 
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24, and 48 h.p.i. via an intra-abscess injection, propionate treatment reduced abscess 
size and weight (Fig. 9A-C). Although the bacterial load slightly decreased when 
propionate was treated, it did not decrease statistically significantly (P = 0.1547) (Fig. 
9D). These results suggest that propionate ameliorates MRSA skin infection, and 





Figure 6. Propionate reduces bacterial load and dermonecrosis in mouse MRSA 
skin infection. C57BL/6 mice were subcutaneously infected with 3 × 106 CFU 
MRSA USA300 alone (left), or together with 50 mM acetate, propionate, or butyrate 
(right) (n = 10-14 per group). (A) Images of abscesses on day 3. Scale bars indicate 
1 cm. On day 3, after euthanasia of mice, (B) size and (C) weight of abscesses were 
measured. (D) Bacterial load was measured by excising and homogenizing abscesses 
aseptically, and spotting homogenates on TSB agar plates. Homogenates were 
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centrifuged and the supernatants were used to measure (E) IL-1β and (F) IL-6. (G) 
Abscesses were cryosectioned and evaluated for histopathology by H&E staining 
and Gram staining. Scale bars indicate 200 μm and 20 μm for top and bottom panels, 
respectively. Data are represented as mean values ± SEM, and statistical significance 
was measured with the paired student’s t-test. *, P < 0.05, **, P < 0.01, ***, P < 




Figure 7. SCFAs do not cause pathology in vivo. C57BL/6 mice were 
subcutaneously injected with endotoxin-free water, or 50 mM propionate, acetate, or 
butyrate (n = 4). (A) Images of injected area on day 3. Scale bar indicates 1 cm. 
There was no abscess formation so (B) abscess size and (C) abscess weight could 
not be measured. (D) The injected areas were excised, homogenized, and plated on 
TSB agar plates to measure bacterial load. Homogenates for endotoxin-free water or 
propionate were centrifuged and supernatants were used to measure (E) IL-1β and 
(F) IL-6 for endotoxin-free water and propionate. Data are represented as mean 
values ± SEM, and statistical significance was measured with the paired student’s t-
test. NaP, propionate; NaA, acetate; NaB, butyrate. 
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Figure 8. Propionate does not affect abscess formation by heat-killed MRSA. 
C57BL/6 mice (n = 3) were subcutaneously injected with (A-C) 1 × 108, or (D-F) 1 
× 109 CFU heat-killed MRSA alone, or with 50 mM propionate. (A, D) Images of 
abscesses on day 3. (B, E) Abscess size and (C, F) abscess weight were measured. 
Data are represented as mean values ± SEM, and statistical significance was 




Figure 9. Propionate reduces abscess formation when treated after MRSA 
infection is initiated. (A) C57BL/6 mice (n = 8) were subcutaneously infected with 
3 × 106 CFU MRSA USA300. Propionate (50 mM) was injected directly into the 
abscess at 1, 24, and 48 h post-infection (h.p.i.). Endotoxin-free distilled water was 
administered as vehicle control. On day 3, (B) abscess size and (C) abscess weight 
were measured. (D) Abscesses were excised, homogenized, and plated on TSB agar 
plates to measure bacterial load. Data are represented as mean values ± SEM, and 
statistical significance was measured with the paired student’s t-test. *, P < 0.05, **, 
P < 0.01. NaP, propionate. 
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3.3. S. aureus with D-alanine-deficient LTA and WTA is more susceptible to the 
growth inhibition by propionate 
In Gram-positive bacteria, cell wall components such as LTA, WTA and LPP play 
important roles in bacterial growth, division, and antimicrobial susceptibility (Fig. 
10) [58-60]. To gain insight into the action mechanism of the growth inhibition by 
propionate, the effects of SCFAs on the growth of WT, ΔltaS, ΔtagO, Δlgt S. aureus 
(Fig. 10C) were compared. First, the dose-dependent effects of acetate, propionate, 
or butyrate on WT S. aureus were confirmed (Fig. 11A-C). Compared to the WT, 
LTA-deficient or WTA-deficient S. aureus was more susceptible to the growth 
inhibition by propionate (Fig. 12A-C), while LPP-deficient S. aureus exhibited a 
similar growth pattern (Fig. 12D). Complement strains of each mutant had more 
similar growth patterns compared to the WT (Fig. 12E-G). Since LTA and WTA share 
D-alanine motifs in common [61], the effects of SCFAs on the growth of S. aureus 
which lacks D-alanine motifs on teichoic acids, which are important for antimicrobial 
peptide and antibiotic resistance [62, 63], were examined. Interestingly, D-
alanylation-deficient S. aureus was substantially more susceptible to propionate than 
the WT, its growth being almost completely inhibited (Fig. 13A, B). Moreover, the 
MIC of propionate for D-alanylation-deficient S. aureus was 62.5 mM, a value four-
fold lower than that for the WT (Fig. 13D, E). As expected, the complement strain 
had similar growth patterns as the WT (Fig. 13C) and had an equal MIC value (Fig. 
13F). Therefore, D-alanine motifs of teichoic acids are important in modulating the 




Figure 10. Cell wall components of S. aureus. (A) The major cell wall components 
of S. aureus are LTA, WTA, and LPP. LTA, which is linked to the cell membrane, 
plays an important role in cell division and membrane homeostasis. WTA is 
covalently linked to the peptidoglycan, and plays an important role in cell division 
and antibiotic resistance. LPP is anchored to the membrane and is important for 
physiology and nutrient acquisition. D-Alanine motifs, on both LTA and WTA, play 
a role in antimicrobial peptide resistance. (B) Schematic structures of LTA and WTA. 
Gro, glycerol; Glc, glucose; P, phosphate; +, D-alanine; GlcNAc, N-
acetylglucosamine; ManNAc, N-acetylmannosamine, Rto, ribitol. (C) Simplified 
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schematic of the synthesis steps of each cell wall component. LTA is synthesized by 
LtaA and LtaS, which form the polyglycerolphosphate chain. WTA is synthesized by 
Tag and Tar enzymes, which connect glycerol or ribitol groups. LPP is synthesized 
via Lgt and Lsp enzymes. The dltABCD operon is responsible for D-alanylation of 





Figure 11. Propionate potently inhibits the growth of S. aureus in a dose-
dependent manner. S. aureus RN4220 was cultured with different doses of (A) 
acetate, (B) propionate, or (C) butyrate. The optical density at 600 nm was measured. 
Data shown are the mean values ± SD of triplicate samples and are representative of 




Figure 12. LTA-deficient or WTA-deficient S. aureus is susceptible to the growth 
inhibition by propionate. (A) WT (B) ΔltaS, (C) ΔtagO, (D) Δlgt, (E) 
ΔltaS/pM101-ltaS, (F) ΔtagO/pStagO, or (G) Δlgt/pSlgt was inoculated and cultured 
in the presence or absence of 12.5 mM of acetate, propionate, or butyrate. The optical 
density at 600 nm was measured. Data shown are the mean values ± SD of triplicate 
samples and are representative of at least three similar independent experiments. 
NaA, acetate; NaP, propionate; NaB, butyrate. 
33 
 
Figure 13. S. aureus with D-alanine-deficient LTA and WTA is susceptible to the 
growth inhibition by propionate. (A) WT (B) ΔdltA, or (C) ΔdltA/p0793 was 
inoculated and cultured in the presence or absence of 12.5 mM of acetate, propionate, 
or butyrate. The optical density at 600 nm was measured. (D-F) The MIC/MBC test 
for propionate was conducted using the microdilution method with (D) WT, (E) 
ΔdltA, or (F) ΔdltA/p0793. The MIC, the concentration of propionate which 
completely inhibited growth, is indicated with an arrow. Data shown are the mean 
values ± SD of triplicate samples and are representative of at least three similar 
independent experiments. NaA, acetate; NaP, propionate; NaB, butyrate. 
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3.4. D-Alanylation inhibition increases susceptibility of MRSA to the growth 
inhibition by propionate 
Next, the importance of D-alanine residues in the growth inhibition by propionate 
was also investigated in MRSA. A D-alanylation inhibitor, AMSA, which inhibits 
DltB, the transmembrane involved in D-alanylation of teichoic acids [64], was used. 
When MRSA was cultured in the presence of different concentrations of AMSA, the 
growth of MRSA was minimally affected upto 25 μg/ml (Fig. 14A). The MIC of 
AMSA was 100 μg/ml (Fig. 14B). AMSA was used at 10 μg/ml, a concentration that 
inhibits D-alanylation, but has minimal effects on bacterial growth, for combination 
experiments. Co-treatment of 10 μg/ml AMSA and 50 mM propionate resulted in 
approximately 80% inhibition of MRSA growth (Fig. 14C). Moreover, the MIC of 
propionate was reduced two-fold to 125 mM when AMSA was co-treated (Fig. 14D). 
In addition, analysis with the checkerboard assay for the FICI demonstrated that 
propionate and AMSA have partial synergy (FICI = 0.6). These results indicate that 
D-alanine residues on teichoic acids are important in modulating the susceptibility of 




Figure 14. D-Alanylation inhibition increases the susceptibility of MRSA to the 
growth inhibition by propionate. (A) MRSA was cultured in the presence of 
different doses of AMSA, a D-alanylation inhibitor. Optical density at 600 nm was 
measured. (B) The MIC/MBC test was conducted using the microdilution method 
with AMSA. The MIC, the concentration of propionate which completely inhibited 
growth, is indicated with an arrow. (C) MRSA USA300 was cultured in the presence 
of 10 μg/ml AMSA, 50 mM propionate, or both. Optical density at 600 nm was 
measured. (D) The MIC/MBC test was conducted using the microdilution method 
with propionate in the presence of 10 μg/ml AMSA. The MIC, the concentration of 
propionate which completely inhibited growth, is indicated with an arrow. Data 
shown are the mean values ± SD of triplicate samples and are representative of at 
least three independent experiments. NaP, propionate. 
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3.5. Co-treatment of a D-alanylation inhibitor and propionate further 
ameliorates MRSA skin infection 
Since the co-treatment of AMSA and propionate led to almost complete inhibition of 
MRSA in vitro, their effects were also studied in vivo. To confirm that the 
concentration of AMSA used in this study is not toxic, mice were injected with 
AMSA only, or with AMSA and propionate. AMSA at 10 μg/ml was not toxic in vivo 
and did not result in pathology or cytokine expression (Fig. 15). In addition, as 
control, the effects of AMSA alone was studied by comparing mice infected with 
MRSA and AMSA to those infected with MRSA alone. Moreover, although AMSA 
slightly decreased the abscess size, it did not affect abscess weight, bacterial load, 
and cytokine expression (Fig. 15). To determine the effect of combination treatment, 
mice were subcutaneously infected with MRSA together with propionate, or with 
AMSA and propionate. Co-injection of AMSA and propionate further reduced 
abscess size and weight compared to injection of propionate alone (Fig. 16A-C). 
Furthermore, combination of AMSA and propionate further reduced the bacterial 
load and excessive cytokine expression (Fig. 16D-F). Therefore, these results 
indicate that co-treatment of AMSA and propionate further ameliorates MRSA skin 




Figure 15. AMSA is not toxic in vivo, and AMSA alone does not reduce the 
pathology of MRSA infection. C57BL/6 mice were subcutaneously injected with 
AMSA, AMSA + propionate, MRSA, or MRSA + AMSA (n = 4). (A) Images of 
injection sites on day 3. Scale bar indicates 1 cm. Then, after euthanasia of mice, (B) 
the size and (C) weight of abscesses were measured. (D) Bacterial load was 
measured by excising and homogenizing abscesses aseptically, and spotting 
homogenates on TSB agar plates. Homogenates were centrifuged and the 
supernatants were used to measure (E) IL-1β and (F) IL-6 by ELISA. Data are 
represented as mean values ± SEM, and statistical significance was measured with 
the paired student’s t test. *, P < 0.05. NaP, propionate. 
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Figure 16. Propionate reduces bacterial load in murine skin infection when co-
treated with a D-alanylation inhibitor. C57BL/6 mice were subcutaneously 
infected with 3 × 106 CFU MRSA USA300 together with 50 mM propionate (left), 
or with 50 mM propionate and 10 μg/ml AMSA (right) (n = 10). (A) Images of 
abscesses on day 3. Scale bar indicates 1 cm. On day 3, after euthanasia, (B) size and 
(C) weight of abscesses were measured. (D) Bacterial load was measured by excising 
and homogenizing abscesses aseptically, and spotting homogenates on TSB agar 
plates. Homogenates were centrifuged and the supernatants were used to measure (E) 
IL-1β and (F) IL-6. Data are represented as mean values ± SEM, and statistical 
significance was measured with the paired student’s t-test. *, P < 0.05. NaP, 
propionate. 
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3.6. Propionate interferes with S. aureus metabolism 
Bacteriostatic agents are likely to change the metabolic state of the bacterium, 
attenuating cellular respiration [65]. In S. aureus, the central metabolic pathway 
involves glycolysis, gluconeogenesis, and tricarboxylic acid (TCA) cycle (Fig. 17) 
[66]. To investigate the mechanisms by which propionate inhibits the growth of S. 
aureus, the effects of propionate on MRSA deficient of metabolic enzymes were 
studied. Compared to the WT (Fig. 18A), MRSA deficient of a gluconeogenesis 
enzyme was more susceptible to propionate (Fig. 18B), while MRSA deficient of a 
glycolytic enzyme was not (Fig. 18C). Moreover, MRSA deficient of TCA cycle 
enzymes was more susceptible to propionate (Fig. 19), suggesting that propionate 




Figure 17. Central metabolic pathways of S. aureus. In S. aureus, the central 
carbon metabolism involves glycolysis, gluconeogenesis, and TCA cycle, along with 




Figure 18. MRSA deficient of a gluconeogenesis enzyme is more susceptible to 
propionate. MRSA (A) WT, (B) glycolysis mutant (Δpyk), or (C) gluconeogenesis 
mutant (ΔpckA) was cultured in the presence or absence of 50 mM propionate. 
Optical density at 600 nm was measured. Data shown are the mean values ± SD of 
triplicate samples and are representative of at least three similar independent 
experiments. NaP, propionate. 
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Figure 19. MRSA deficient of TCA cycle enzymes is more susceptible to 
propionate. MRSA (A) WT or TCA cycle mutant (B) ΔacnA, (C) Δicd, (D) ΔsucA, 
(E) ΔsucC, (F) ΔsdhA, (G) ΔfumC, (H) Δmqo, or (I) ΔgltA, was cultured in the 
presence or absence of 50 mM propionate. Optical density at 600 nm was measured. 
Data shown are the mean values ± SD of triplicate samples and are representative of 
at least three similar independent experiments. NaP, propionate. 
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3.7. Propionate inhibits the growth of other pathogens 
To determine if the bacteriostatic effect of propionate is unique to S. aureus, the 
effect of propionate on other bacteria was studied. The degree of susceptibility varied 
among the tested bacteria. The growth of S. pneumoniae (Fig. 20A) or E. faecium 
(Fig. 20B) was potently inhibited, while the growth of S. epidermidis (Fig. 20C) or 
E. faecalis (Fig. 20D) was moderately inhibited. The growth of S. gordonii (Fig. 20E) 
or L. plantarum (Fig. 20F) was not inhibited by propionate. Thus, the susceptibility 
of propionate seems to vary depending on the bacterial species. Collectively, the 
results of this study indicate that propionate inhibits the growth of S. aureus both in 
vitro and in vivo, and that D-alanine motifs modulate the susceptibility of S. aureus 
to propionate (Fig. 21). These suggest propionate, together with a D-alanylation 






Figure 20. Propionate inhibits the growth of other pathogens. (A) S. pneumoniae, 
(B) E. faecium, (C) S. epidermidis, (D) E. faecalis, (E) S. gordonii, and (F) L. 
plantarum were cultured in the presence or absence or 50 mM propionate. Optical 
density at 600 nm was measured. Data shown are the mean values ± SD of triplicate 





Figure 21. Schematic illustration of the proposed action mechanism of 
propionate. Propionate inhibits the growth of S. aureus. D-Alanylation-deficient S. 
aureus is more susceptible to the growth inhibition by propionate. D-Alanine motifs 
on teichoic acids of S. aureus modulate the susceptibility of S. aureus to propionate. 
Propionate is likely to be able to diffuse into S. aureus more readily because of the 
decreased cell wall density due to the absence of D-alanine motifs. 
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Chapter IV. Discussion 
Since the prevalence in infections caused by multidrug-resistant S. aureus is 
increasing, and there is a limited availability of antibiotics along with possible side 
effects, alternative therapeutic strategies against S. aureus infections are urgently 
needed. To overcome multidrug-resistant S. aureus infections, combination therapy 
and the concept of synthetic lethality have been gaining more attention [25, 26]. 
Combination therapy has been thought to be more effective and less prone to 
resistance [67]. If there were synergy between the therapeutic agents, the amounts of 
the agents used may also be reduced. In the present study, propionate inhibited the 
growth of S. aureus including multidrug-resistant strains, likely by interfering with 
bacterial metabolism, and ameliorated MRSA skin infection, which represents a 
majority of MRSA infections. In addition, a combination treatment of propionate and 
AMSA, a D-alanylation inhibitor, more potently inhibited MRSA infection, 
suggesting combination treatment as an efficient alternative strategy for control of 
multidrug-resistant S. aureus infections. 
 
Of the three SCFAs, propionate most potently inhibited the growth of MRSA both 
in vitro and in vivo. The inhibitory effect of propionate seems to be a general 
phenomenon in S. aureus, since propionate inhibited the growth of all strains of S. 
aureus tested, including clinically isolated multidrug-resistant S. aureus. Similarly, 
it has been previously suggested that the fermentation products of P. acnes, which 
contain butyric acid, 3-hydroxy-butyric acid, lactic acid, propionic acid, and ethanol, 
can interfere with S. aureus colonization in a wound model [45]. Although the 
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involvement of other proteins or metabolites cannot be excluded, propionic acid 
seems to have been responsible for colonization interference as propionic acid of pH 
3.5 inhibited S. aureus colonization as well. In addition, another study has reported 
the growth inhibitory properties of propionic acid, which changes the pH of the 
extracellular medium [46]. Since a high concentration of propionic acid may result 
in an acidic environment, propionic acid could lead to side effects such as skin 
irritation or corrosion [68]. Therefore, in this study, propionate, which is not acidic 
and does not change the extracellular pH, was used. Propionate inhibited S. aureus 
growth and ameliorated MRSA skin infection without affecting the pH of the 
extracellular environment. 
 
It has been suggested that bacteriostatic agents can change the metabolic state of the 
bacterium and interfere with its metabolism [65]. Propionate might interfere with 
metabolic pathways that are important for S. aureus growth, such as cellular 
respiratory pathways including glycolysis, TCA cycle, or oxidative phosphorylation. 
Indeed, MRSA deficient of a gluconeogenesis enzyme or a TCA cycle enzyme was 
more susceptible to propionate, suggesting a possible relationship. In addition, it has 
been reported that propionate inhibits the growth of Rhodopseudomonas sphaeroides 
by interfering with pyruvate decarboxylation [69]. The authors suggested that 
propionate gets converted to propionyl-CoA, which then interferes with the pyruvate 
dehydrogenase complex. Since S. aureus also has a putative propionate CoA-
transferase [70], propionate may also be converted to propionyl-CoA and interfere 
with pyruvate decarboxylation in S. aureus as well. Moreover, since propionate 
potently inhibited the growth of S. aureus while acetate and butyrate did not, it is 
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likely that propionate would uniquely target a specific pathway that the other SCFAs 
do not. Acetate or butyrate may not interfere with metabolism, since acetate is 
produced by S. aureus and can enter the TCA cycle, and since butyrate can be 
produced through fermentative metabolism [71, 72]. Although further studies are 
needed to address the possible mechanisms, propionate seems to affect the metabolic 
pathways of S. aureus. 
 
S. aureus was more susceptible to the growth inhibition by propionate when D-
alanine motifs on LTA and WTA are absent, demonstrated by using D-alanylation-
deficient S. aureus, and a D-alanylation inhibitor. D-Alanylation residues on LTA and 
WTA are important for many physiological processes, including regulation of 
autolytic enzymes, colonization, and virulence [73-75]. Furthermore, the absence of 
D-alanylation leads to increased susceptibility of bacteria to antimicrobial peptides, 
antibiotics, and neutrophil killing [62, 63, 74]. It has been reported that D-alanylation 
of teichoic acids increases the cell wall density and rigidity, and that D-alanine 
residues confer resistance to antimicrobial peptides by decreasing permeability, 
rather than by conferring positive charges [76]. It is likely that when D-alanine 
residues on teichoic acids are absent, propionate may be able to diffuse more easily 
into S. aureus to interfere with bacterial metabolism. In addition, the varying degree 
of susceptibility among the different strains of S. aureus tested may have been due 
to differences in the level of D-alanylation of teichoic acids, considering that 
antibiotic-resistant S. aureus clinical isolates have been reported to have increased 
D-alanylation [77]. Even though further studies are needed to elucidate the 
connection between propionate susceptibility and D-alanylation, a correlation may 
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exist, and combination therapy of propionate and a D-alanylation inhibitor may be an 
effective strategy to control multidrug-resistant S. aureus infections. Furthermore, 
inhibitors that target other cell wall components such as teichoic acids may also have 
potential as combination therapy agents. 
 
Propionate significantly decreased the pathology of MRSA skin infection, and 
lowered abscess formation, bacterial load, and excessive cytokine expression. 
SCFAs are well-known to exhibit immunomodulatory effects [32]. In this study, the 
amelioration of MRSA skin infection is more likely to have been due to the reduced 
absolute number of bacteria and the bacteriostatic activity of propionate, since 
propionate did not change the size and weight of abscess formed by subcutaneous 
injection of heat-killed MRSA. In addition, another bacteriostatic agent had 
antibacterial effects in S. aureus lung infection [78]. Although the 
immunomodulatory effect of propionate cannot be excluded, it is likely that the 
effect of propionate on the host immune system is more minor compared to its effect 
on S. aureus itself. Butyrate is known to more potently regulate the immune system 
than propionate [79, 80], but butyrate did not decrease pathology in these 
experimental conditions. Moreover, IL-1β and IL-6 expression decreased when the 
bacterial load was lower, suggesting that cytokine expression was decreased because 
of a reduction in the absolute number of bacteria. Although IL-1β is important for 
immunity against S. aureus infection [5], excessive IL-1β production has detrimental 
effects [6]. When propionate is treated, there would have been less excessive 
inflammation caused by IL-1β and IL-6 released from neutrophils, the key cell type 
in S. aureus skin infection. In addition, since targeting bacteria with AMSA further 
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ameliorated MRSA skin infection, the decreased pathology of MRSA seems to be a 
result of decreased bacterial load. Therefore, propionate ameliorates MRSA skin 
infection by attenuating bacterial growth, and the effect of propionate on the host 
seems to be more minor. 
 
Interestingly, different bacterial species had varying susceptibility to propionate. For 
example, pathogens S. pneumoniae and E. faecium were highly susceptible, while 
commensals S. epidermidis and E. faecalis were moderately susceptible. Commensal 
S. gordonii and probiotic L. plantarum were not susceptible to 50 mM propionate. 
The varying effects of SCFAs depending on bacterial species have been previously 
suggested as well [81]. SCFAs have been suggested to inhibit the growth or virulence 
of pathogenic bacteria [41, 43, 81]. Coincidently, in this study, pathogenic bacteria 
were more susceptible to propionate than commensal or probiotic bacteria. 
Commensal and probiotic bacteria were less or not susceptible to the growth 
inhibition by propionate. Since SCFAs also exist systemically, probiotic and 
commensal bacteria may have adapted to be tolerant to SCFAs because they are 
frequently exposed to SCFAs. In addition, the varying susceptibility may be due to 
differences in the level of D-alanylation of teichoic acids among the different 
bacterial species, considering that S. aureus was more susceptible to propionate 
when D-alanine motifs were absent. Although this needs further investigation, 
propionate may selectively inhibit the growth of pathogenic bacteria. 
 
In this study, propionate inhibited the growth of MRSA and other clinically isolated 
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multidrug-resistant S. aureus, and ameliorated MRSA skin infection. Since 
propionate was not toxic in vivo, and since it is a beneficial metabolite present in our 
body, it is biocompatible, and is likely to have fewer or no side effects. Interventions 
that increase propionate production in the host, or deliver propionate directly to the 
host [82] may be applied for S. aureus infections. In SSTIs, propionate might be 
applied to the abscess after incision and drainage [22] to directly control S. aureus 
growth, and therefore decrease excessive inflammation and lead to infection control. 
Moreover, since resistance against topical antimicrobials has emerged, propionate 
may be applied as an ointment to a skin wound to prevent infection by S. aureus. 
Furthermore, co-treatment of propionate and a D-alanylation inhibitor had a 
synergistic effect, almost completely inhibiting in vitro MRSA growth, and further 
reduced dermonecrosis in vivo. As combination therapy is less prone to resistance, 
and has been suggested as a way to combat antibiotic-resistant S. aureus infections, 
propionate may be used in combination with other antibiotics that target D-alanine 
motifs, or other bacterial cell wall components. Taken together, these results suggest 
an alternative strategy using propionate to control antibiotic-resistant S. aureus 




Figure 22. Clinical application of propionate and significance. Upon S. aureus 
skin infection, S. aureus will proliferate rapidly, and neutrophils would be recruited. 
S. aureus can evade neutrophil killing and also induce neutrophil lysis. S. aureus will 
escape and cause excessive inflammation and tissue damage. If propionate were used, 
the growth of S. aureus would be inhibited. Excessive inflammation would decrease, 
and the infection would be controlled. Since propionate is a metabolite and did not 
cause pathology, it might be used to control S. aureus infections without toxicity. 
Also, combination therapy of propionate with AMSA, a D-alanylation inhibitor, or 
another cell wall component inhibitor, might be an efficient strategy that is less prone 
to resistance to control antibiotic-resistant S. aureus infections. 
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Propionate에 의한 황색포도상구균 









황색포도상구균(Staphylococcus aureus)은 그람양성세균으로 피부 및 연
조직 감염, 폐렴, 장염과 패혈증 같은 다양한 질병을 유발하는 병원균이다. 
특히, 항생제 내성을 가진 S. aureus가 증가하면서 치료에 어려움을 겪고 
있고, 메티실린 내성을 가진 S. aureus (methicillin-resistant S. aureus, 
MRSA)와 다제내성 S. aureus에 의한 감염을 제어할 방법이 없기 때문에 
문제가 되고 있다. 단쇄지방산은 장내 미생물의 대사물질 중 하나로, 숙주
의 장내 건강과 면역 항상성에 중요한 것으로 알려져 있다. 최근에는 단쇄
지방산이 미생물에 성장 또는 병독성을 억제할 수 있다는 것이 보고된 바 
있다. 하지만 단쇄지방산 acetate, propionate, 또는 butyrate가 황색포도
상구균에 미치는 영향은 알려져 있지 않다. 따라서 본 연구에서는 단쇄지
방산이 항생제 내성 균주를 포함한 황색포도상구균의 성장과 마우스 피부
감염에 미치는 영향을 알아보았다. 
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2. 방법 
단쇄지방산이 황색포도상구균의 성장에 미치는 영향을 알아보기 위해 여러 
농도의 acetate, propionate, 또는 butyrate를 처리한 후 분광광도계로 
흡광도를 측정하여 성장을 측정하였다. 단쇄지방산이 정균적 또는 살균적 
효과를 가지는지 보기위해 minimum inhibitory 
concentration/minimum bactericidal concentration 테스트를 진행하였
다. 황색포도상구균의 형태를 주사전자현미경을 통해 확인하였다. 또한, 단
쇄지방산이 MRSA 피부감염에 미치는 영향을 알아보기 위해 마우스에 
MRSA 또는 MRSA와 단쇄지방산을 피하주사로 감염시키고 형성된 농양의 
크기와 무게를 측정하였다. 농양을 균질화 하여 MRSA의 양을 측정하였고, 
상층액에서 interleukin (IL)-1β와 IL-6를 효소결합 면역분석법을 통해 측
정하였다. 농양을 동결절편을 하여 hematoxylin & eosin 염색과 그람 염
색을 통해 조직학적 분석을 하였다. 황색포도상구균의 세포벽 물질과 단쇄
지방산에 의한 성장 억제의 관련성을 알아보기 위해 lipoteichoic acid 
(LTA), wall teichoic acid (WTA), lipoprotein, 또는 teichoic acid의 D-
alanine분자가 결손 된 황색포도상구균을 사용하여 야생형 균주와 비교하
였다. 또한, MRSA에 D-alanylation 억제제를 이용하여 성장을 측정하고 
단쇄지방산과의 병용처리의 효과를 확인하였다. 단쇄지방산의 작용기전을 
알아보기 위해 대사에 관련된 효소가 결손 된 MRSA를 사용하여 성장을 
측정하였다. 단쇄지방산이 다른 세균에 미치는 영향 또한 확인하였다. 
3. 결과 
단쇄지방산 중 propionate가 가장 효과적으로 MRSA의 성장을 억제하였
으며 propionate는 실제 환자에게서 분리 된 균주와 다제내성 균주를 포
함한 모든 황색포도상구균의 성장을 억제하였다. Propionate는 MRSA 피
부감염에서 농양 형성, MRSA의 수 및 과도한 IL-1β와 IL-6 생성을 억제
하였다. 또한, propionate는 MRSA 감염이 시작된 후에 처리되었을 때에
도 농양 형성을 감소시켰다. LTA 또는 WTA가 결손 된 경우 단쇄지방산에 
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의해 성장이 더 억제 되었고, teichoic acid에 공통적으로 존재하는 D-
alanine이 결손 된 경우 propionate에 의한 성장억제에 더 민감하였다. 
D-Alanylation 억제제를 처리한 MRSA 또한 propionate에 의해 성장이 
더 억제 되었고, D-alanylation 억제제와 propionate를 병용처리 하였을 
때 농양 형성, MRSA의 수와 과도한 싸이토카인 생성이 억제되어 MRSA 
피부감염이 더욱 완화되는 것을 확인하였다. 해당과정의 효소가 결손 된 
MRSA는 propionate에 의해 비슷한 정도로 억제 되었지만, 포도당신생합
성의 효소가 결손 된 MRSA는 성장이 더 많이 억제 되었다. Tricarboxylic 
acid 회로 효소가 결손 된 경우 또한 성장이 더 많이 억제 되어 
propionate와 대사의 관계성을 확인하였다. Propionate는 황색포도상구균 
뿐 아니라 다른 병원균, 폐렴구균(Streptococcus pneumoniae)과 장구균 
Enterococcus faecium의 성장을 억제하였고, 공생균 표피포도상구균
(Staphylococcus epidermidis), 장구균 Enterococcus faecalis의 성장을 
약간 억제하였으나 공생균 Streptococcus gordonii와 유산균 
Lactobacillus plantarum의 성장은 억제하지 않았다. 
4. 결론 
본 연구에서는 propionate가 다제내성 균주 및 실제 환자에서 분리된 균
주를 포함한 여러 황색포도상구균의 성장을 억제하였고 MRSA 피부감염을 
완화시켰다. Propionate와 D-alanylation 억제제를 병용처리 한다면 다제
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